Skip to main content

Table 1 Baseline and 12-week post-treatment measures of obesity

From: Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study

 

MET (n = 13)

LIRA (n = 14)

ROF (n = 14)

P values

Baseline

After therapy

Baseline

After therapy

Baseline

After therapy

Weight (kg)

108.3 ± 17.0

108.1 ± 17.5

102.8 ± 16.3

99.7 ± 17.2

111.1 ± 16.1

109.0 ± 16.4

T = 0.025 (L vs. M = 0.022); I (L = 0.006; R = 0.002)

BMI (kg/m2)

39.4 ± 6.9

39.3 ± 7.0

36.7 ± 5.6

35.6 ± 5.8

39.9 ± 5.4

39.1 ± 5.7

T = 0.023 (L vs. M = 0.020); I (L = 0.006; R = 0.001)

Waist circumference (cm)

120.5 ± 14.5

121.3 ± 13.2

115.7 ± 12.5

112.6 ± 12.9

123.0 ± 15.9

121.8 ± 16.1

T = 0.009 (L vs. M = 0.007); I (L = 0.009; R = 0.023)

VAT area (cm2)

131 ± 44.5

126.5 ± 48.3

160.3 ± 67.9

140.7 ± 60.8

157.3 ± 36.7

153.7 ± 21.9

I (L = 0.015)

  1. For p values, T = overall effect after all treatments, R = ROF, L = LIRA, M = MET, I = interaction differences between treatment over trials